Consequently, different groups are developing small drug CXCR4 inhibitors for AML therapy [5, 7, 18] aimed at eliminating CXCR4+ LSCs, responsible for AML aggressiveness and patient death. Here, CXCR4 is linked to acute myeloid leukemia.